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Abstract 
Review on CEBPE, with data on DNA, on the 
protein encoded, and where the gene is implicated. 
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Identity 
Other names: CRP1 
HGNC (Hugo): CEBPE 
Location: 14q11.2 
Location (base pair) 
Starts at 23117306 and ends at 23119611 bp from 
pter (according to GRCh38.p7 Annotation Release 
108, May 5 2016) 
DNA/RNA 
Description 
CEBPE is located on chromosome 14q11.2 in a 
telomer-centromer orientation. Conflicting data 
have been published on the gene structure of 
CEBPE. According to the GRCh38.p7 assembly 
annotation (2016/03/21) the gene consists of two 
exons (1030 bp and 517 bp), which are partially 
coding and separated by a 759 bp intron (Figure 
1a). 
This is in conflict with some previously published 
papers. Yamanaka et al. (1997) described an  
alternative 3-exon-organization of the human 
CEBPE gene (Figure 1b). However, exon 1, as 
described by Yamanaka et al. contains a frameshift 
according to the GRCh38.p7 NCBI assembly. 
Transcription 
Various transcripts have been reported, resulting in 
four protein isoforms (Lekstrom-Himes 2001, 
Yamanaka 1997; Figure 1c). All transcripts share a 
common 3' end. 
Protein 
Description 
CEBPE is a member of the CCAAT/enhancer-
binding protein (C/EBP) family, which also 
includes CEBPA, CEBPB, CEBPG, CEBPD and 
CEBPZ (Ramji & Foka; 2002). A common 
structural feature of the C/EBP proteins is the 
presence of a highly conserved 55-65 amino acid 
sequence at the C-terminus which encodes a basic 
leucine zipper motif (bZIP domain) that functions 
as a dimerization domain. In the aminoterminal part 
all C/EBP proteins possess a DNA-binding domain 
with relative specificity for the CCAAT DNA 
motif. C/EBP proteins exert their physiological 
functions as either homo- or heterodimers. They 
can also interact with other bZIP- and non-bZIP 
transcription factors. Different protein domains 
have been characterized. The full-length CEBPE 
protein basically consists of an activation domain at 
the aminoterminal end, a repression domain in the 
center and the leucine zipper at the carboxyterminus 
(Williamson et al. 1998).  
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Figure 1: Human CEBPE gene and mRNA transcript:  a. according to the GRCh38.p7 assembly annotation (2016/03/21); b. 
according to Yamanaka et al. (1997); c. transcripts based on the Yamanaka exon organization 
 
At least four different CEBPE protein isoforms of 
32, 30, 27, and 14 kDa have been described, but 
their functional significance is unclear (Lekstrom-
Hines et al. 2001, Figure 1c).  
The CEBPE translation product can undergo a 
number of post-translational modifications. 
Phosphorylation of CEBPE on threonine 75, 
located in the transactivation domain, is associated 
with increased DNA binding capacity and 
transcriptional activation (Williamson et al., 2005). 
Sumoylation of lysine residues within the 
repression domain has been found to modulate 
CEBPE function (Kim et al., 2005). Acetylation of 
lysine-121 and lysine-198 was found to be critical 
for terminal neutrophil differentiation (Bartels et. 
al., 2015). 
Expression 
CEBPE is predominantly expressed in cells of the 
hematopoietic system and to a much lesser extent in 
ovarian tissue (Yamanaka, et al., 1997). In normal 
hematopoietic cells CEBPE is preferentially 
expressed in myeloid-committed cells and the 
protein is virtually only detectable in 
metamyelocytes and myelocytes. The gene is also 
expressed in more immature myeloid cells but 
protein translation is repressed by miRNA-130a 
(Larsen et al., 2014).  
 
The expression of CEBPE protein induces growth 
arrest, morphological differentiation, secondary 
granule proteins and has proapoptotic effects 




CEBPE is a transcription factor, important for 
monocyte and granulocyte development. The 
transcription factor binds as a homodimer or 
heterodimer (with CEBPD) to specific DNA 
regulatory regions. Shorter CEBPE protein 
isoforms are hypothetical attenuators of the 
transcriptional activity of the long isoform.  
Homozygous CEBPE knock-out (-/-) mice appear 
healthy at birth but survive only 2-5 months after 
birth, while heterozygous CEBPE knock-out mice 
appear normal. CEBPE (-/-) mice showed a marked 
increase in immature myeloid progenitors, 
increased numbers of morphologically abnormal 
neutrophils, that were functionally defect and 
lacked an oxidative burst, and decreased numbers 
of eosinophils. Thus it was concluded that CEBPE 
is essential for a normal terminal differentiation of 
committed granulocyte progenitor cells (Yamanaka, 
et al., 1997). 
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Implicated in 
Neutrophil specific granule 
deficiency (SGD) 
Some, but not all of the very few known patients 
with SGD harboured CEBPE mutations which led 
to loss of the dimerization domain; phenotypically, 
SGD patients show bilobed nuclei, impaired 
chemotaxis and bactericidal activity with 
susceptibility to severe bacterial infections 
(Gombart & Koeffler 2002). 
Acute lymphoblastic leukemia (ALL) 
The CEBPE single nucleotide polymorphism 
rs2239633 has been implicated as a susceptibility 
factor for the development of B lineage ALL in 
children and adults. The relative risk (odds ratio) 
conferred is 1.1-1.6 (Papaemmanuil et al., 2009; 
Burmeister et al. 2014). 
t(14;14)(q11;q32) CEBPE/IGH and 
inv(14)(q11q32) CEBPE/IGH 
CEBPE is found recurrently translocated to the 
immunoglobulin heavy chain locus ( IGH) on 
14q32 in acute lymphoblastic leukemia patients 
with inv(14)(q11q32)/t(14;14)(q11;q32). The 
translocation leads to an overexpression of CEBPE 
under the control of the immunoglobulin heavy 
chain gene promoters. At least five cases have been 
described (Akasaka et al. 2007). 
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